Promising toxicity and pharmacokinetic findings emerge from phase Ia trial of doranidazole Feb. 21, 2001
U.S. and Israeli team prepares short peptides modulating serine/threonine kinase activity Feb. 20, 2001
Antiangiogenic/antitumor compound TSRI-265 specifically disrupts MMP-2 binding to alphavbeta3 Feb. 20, 2001
RSS